echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Roche's new intraocular drug delivery system ranibizumab PDS enters priority review in the United States

    Roche's new intraocular drug delivery system ranibizumab PDS enters priority review in the United States

    • Last Update: 2021-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Roche's Genentech recently announced that the U.


    The FDA is expected to make an approval decision before October 23, 2021


    PDS (Port Delivery System) is a permanent, refillable intraocular implant with a size of about a grain of rice, which can continuously deliver customized formulations of ranibizumab within a few months.


    PDS can be refilled continuously (once every 6 months).


    Dr.


    PDS (picture source-PMID: 30946888)

    PDS BLA submission, based on the positive results of the Phase 3 ARCHWAY study (NCT03677934)


    In addition, the visual results obtained by these patients are consistent with those who received 0.


    The safety of PDS in clinical trials has been fully understood and will continue to be closely monitored


    Schematic diagram of PDS rehydration operation (retinalphysician.


    Neovascular AMD (nAMD) is the main cause of blindness in people aged 60 and over in the world.


    Ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor designed to bind and inhibit VEGF-A, a protein that plays a key role in new blood vessel formation and vascular leakage


    PDS contains a customized formulation of ranibizumab that has not been approved by regulatory agencies.


    By maintaining the therapeutic drug concentration level of ranibizumab by rehydrating twice a year, PDS can provide patients with nAMD with greater certainty of the results in terms of visual gain and maintenance of these gains


    In addition to the ARCHWAY study, the PORTAL study is investigating the long-term safety and tolerability of PDS in the treatment of nAMD


    Original source: FDA Accepts Application for Genentech's Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.